Showing papers by "Omar Serri published in 2007"
TL;DR: The aim of this study was to compare the longterm effects of gliclazide modified release (MR) and glibenclamide on carotid IMT and serum markers of endothelial activation and low-grade inflammation in patients with type 2 diabetes.
Abstract: Patients with type 2 diabetes have a higher cardiovascular morbidity and mortality compared with non-diabetic subjects [1]. The traditional cardiovascular risk factors can account for part of the excess cardiovascular risk indiabetes. Emergingpotential risk factors such as carotid artery intimamedia thickness (IMT), endothelial dysfunction and lowgrade systemic inflammation are now considered [2–5]. The aim of this study was to compare the longterm effects of gliclazide modified release (MR) and glibenclamide on carotid IMT and serum markers of endothelial activation and low-grade inflammation in patients with type 2 diabetes.
28 citations
TL;DR: It is shown in the recent study that C-reactive protein (CRP) was higher in the nonobese patients than in normal controls, suggesting that hyperprolactinaemia independently from obesity was associated with increased CRP, and dopamine D2 receptor stimulation may be beneficial with regard to the control of certain parameters of risk for cardiovascular disease.
Abstract: We thank Schmid and Brändle 2 for their interest in our paper and agree that we have described associations rather than demonstrate a causal relation between hyperprolactinaemia and cardiovascular risk markers. We also agree that dopamine D2 receptor stimulation may be beneficial with regard to the control of certain parameters of risk for cardiovascular disease. The statistics provided by these authors showing a significantly higher mean body mass index (BMI) in patients with macroprolactinoma than in patients with nonfunctioning macroadenoma are of interest and in line with previous findings. Schmid and Brändel questioned the relation between hyperprolactinaemia and cardiac risk markers on the basis that they have not found any study of body weight and insulin resistance in patients treated surgically and nor with dopamine agonists. However, we have described in 1986 3 a series of 15 women with microprolactinoma who had been tested for insulin sensitivity with an insulin tolerance test before and after successful surgical adenoma removal. All patients had normal adrenal and thyroid functions preand postoperatively. Our results have shown that insulin sensitivity was significantly enhanced after surgery, although the mean patients’ weight was unchanged. Furthermore, we have shown in our recent study 1 that C-reactive protein (CRP) was higher in the nonobese (BMI < 30 kg/m 2 ) hyperprolactinaemic patients than in normal controls, suggesting that hyperprolactinaemia independently from obesity was associated with increased CRP.